Analysts Expect Amedisys, Inc. (NASDAQ: AMED) Will Post Quarterly Sales of $ 580.91 Million


Analysts expect Amedisys, Inc. (NASDAQ: AMED – Get Rating) to post $ 580.91 million in sales for the current fiscal quarter, Zacks reports. Eight analysts have made estimates for Amedisys’ earnings, with estimates ranging from $ 560.70 million to $ 592.20 million. Amedisys reported sales of $ 564.17 million in the same quarter last year, which would suggest a positive year over year growth rate of 3%. The business is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Amedisys will report full year sales of $ 2.35 billion for the current financial year, with estimates ranging from $ 2.33 billion to $ 2.36 billion. For the next financial year, analysts expect that the firm will report sales of $ 2.58 billion, with estimates ranging from $ 2.52 billion to $ 2.64 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Amedisys.

Amedisys (NASDAQ: AMED – Get Rating) last announced its quarterly earnings results on Wednesday, April 27th. The health services provider reported $ 1.23 EPS for the quarter, beating analysts’ consensus estimates of $ 1.11 by $ 0.12. The company had revenue of $ 545.26 million during the quarter, compared to analysts’ expectations of $ 557.81 million. Amedisys had a return on equity of 19.37% and a net margin of 8.59%. During the same period in the prior year, the business posted $ 1.54 EPS.

A number of brokerages have recently commented on AMED. BMO Capital Markets raised Amedisys from a “market perform” rating to an “outperform” rating and lowered their price target for the company from $ 210.00 to $ 190.00 in a research note on Friday, February 25th. SVB Leerink increased their target price on Amedisys from $ 145.00 to $ 147.00 and gave the stock a “market perform” rating in a research note on Friday, February 18th. Raymond James lowered their target price on Amedisys from $ 200.00 to $ 180.00 in a research note on Friday, April 29th. Credit Suisse Group lowered their target price on Amedisys from $ 200.00 to $ 195.00 and set an “outperform” rating for the company in a research note on Friday, February 25th. Finally, Oppenheimer reissued an “outperform” rating and set a $ 200.00 target price on shares of Amedisys in a research note on Friday, April 29th. Seven investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $ 191.06.

In other Amedisys news, insider David L. Kemmerly sold 2,500 shares of the firm’s stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $ 177.31, for a total transaction of $ 443,275.00. Following the completion of the sale, the insider now owns 16,336 shares of the company’s stock, valued at approximately $ 2,896,536.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.80% of the company’s stock.

A number of institutional investors have recently made changes to their positions in AMED. Quadrature Capital Ltd increased its position in Amedisys by 375.4% during the 3rd quarter. Quadrature Capital Ltd now owns 33,316 shares of the health services provider’s stock worth $ 4,967,000 after buying an additional 26,308 shares during the period. The New York State Teachers Retirement System increased its position in shares of Amedisys by 7.3% in the fourth quarter. The New York State Teachers Retirement System now owns 44,390 shares of the health services provider’s stock worth $ 7,186,000 after purchasing an additional 3,015 shares during the period. First Trust Advisors LP increased its position in shares of Amedisys by 235.6% in the fourth quarter. First Trust Advisors LP now owns 151,640 shares of the health services provider’s stock worth $ 24,547,000 after purchasing an additional 106,453 shares during the period. Advisor Partners LLC bought a new position in shares of Amedisys in the fourth quarter worth $ 215,000. Finally, Riverbridge Partners LLC increased its position in shares of Amedisys by 57.0% in the fourth quarter. Riverbridge Partners LLC now owns 1,588,750 shares of the health services provider’s stock worth $ 257,187,000 after purchasing an additional 576,633 shares during the period. 90.47% of the stock is owned by institutional investors and hedge funds.

Shares of AMED stock opened at $ 121.57 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.03 and a quick ratio of 1.03. The stock has a market cap of $ 3.96 billion, a PE ratio of 20.92, a price-to-earnings-growth ratio of 2.21 and a beta of 0.88. The stock has a 50-day moving average of $ 148.85 and a 200-day moving average of $ 152.02. Amedisys has a one year low of $ 109.53 and a one year high of $ 276.21.

About Amedisys (Get Rating)

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Stories

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offers from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ: AMED)



Receive News & Ratings for Amedisys Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amedisys and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker